Teladoc Health (TDOC) Receives New Coverage from Analysts at Credit Suisse Group

Credit Suisse Group started coverage on shares of Teladoc Health (NYSE:TDOC) in a research report report published on Monday, The Fly reports. The firm issued a neutral rating and a $80.00 price target on the health services provider’s stock.

Several other equities analysts have also weighed in on TDOC. Oppenheimer boosted their target price on shares of Teladoc Health from $59.00 to $68.00 and gave the company an outperform rating in a report on Thursday, August 2nd. Canaccord Genuity boosted their target price on shares of Teladoc Health from $86.00 to $94.00 and gave the company a buy rating in a report on Friday, September 28th. Cantor Fitzgerald boosted their target price on shares of Teladoc Health from $52.00 to $83.00 and gave the company a neutral rating in a report on Friday, September 28th. They noted that the move was a valuation call. Robert W. Baird boosted their price target on shares of Teladoc Health from $50.00 to $65.00 and gave the company a neutral rating in a research note on Wednesday, July 25th. Finally, Jefferies Financial Group set a $90.00 price target on shares of Teladoc Health and gave the company a buy rating in a research note on Friday, September 28th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of Buy and a consensus price target of $79.79.

NYSE:TDOC opened at $71.00 on Monday. The company has a current ratio of 3.14, a quick ratio of 3.14 and a debt-to-equity ratio of 0.58. The stock has a market capitalization of $6.01 billion, a price-to-earnings ratio of -43.03 and a beta of 0.57. Teladoc Health has a 1-year low of $27.30 and a 1-year high of $89.05.

Teladoc Health (NYSE:TDOC) last posted its earnings results on Wednesday, August 1st. The health services provider reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.01. The company had revenue of $94.60 million for the quarter, compared to analyst estimates of $91.56 million. Teladoc Health had a negative net margin of 37.78% and a negative return on equity of 19.10%. Teladoc Health’s revenue was up 112.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.28) EPS. Equities analysts expect that Teladoc Health will post -1.51 EPS for the current fiscal year.

In related news, insider Stephany Verstraete sold 18,000 shares of the company’s stock in a transaction that occurred on Thursday, September 20th. The shares were sold at an average price of $74.79, for a total transaction of $1,346,220.00. Following the sale, the insider now directly owns 13,925 shares of the company’s stock, valued at approximately $1,041,450.75. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, President Peter A. Mcclennen sold 91,072 shares of the company’s stock in a transaction that occurred on Monday, July 16th. The stock was sold at an average price of $65.84, for a total transaction of $5,996,180.48. Following the sale, the president now directly owns 61,660 shares in the company, valued at $4,059,694.40. The disclosure for this sale can be found here. Insiders sold a total of 263,710 shares of company stock worth $18,604,135 over the last three months. Insiders own 3.95% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. We Are One Seven LLC increased its position in shares of Teladoc Health by 241.1% in the 1st quarter. We Are One Seven LLC now owns 2,845 shares of the health services provider’s stock valued at $115,000 after purchasing an additional 2,011 shares during the last quarter. Garner Asset Management Corp purchased a new stake in shares of Teladoc Health in the 2nd quarter valued at approximately $200,000. Pier 88 Investment Partners LLC purchased a new stake in shares of Teladoc Health in the 2nd quarter valued at approximately $201,000. Aperio Group LLC purchased a new stake in shares of Teladoc Health in the 2nd quarter valued at approximately $201,000. Finally, California Public Employees Retirement System purchased a new stake in shares of Teladoc Health in the 2nd quarter valued at approximately $203,000.

Teladoc Health Company Profile

Teladoc Health, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Featured Article: Understanding Stock Ratings

The Fly

Analyst Recommendations for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply